Bls Pharmaceuticals (ASX:BLS) — Material Events

ASX:BLS · 3 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Major Score 90+

BLS Pharmaceuticals Doubles Revenue and Profit in FY26, Secures $50m German ContractHigh

BLS Pharmaceuticals reports record FY26 revenue and profit, expands international manufacturing and secures major contracts

31 Aug 2026 ·Annual Financial Report ·90

BLS Pharmaceuticals Hits Record $75m Revenue, Locks $50m German Supply DealHigh

BLS Pharmaceuticals reports record FY26 revenue and EBITDA, secures major international supply deals, and advances manufacturing expansion

27 July 2026 ·Quarterly Activities Report ·90

Significant Score 75–89

BLS Pharmaceuticals Posts Record $22.5m Q4 Revenue, Expands Global Manufacturing FootprintMedium

BLS Pharmaceuticals reports record Q4 FY2026 revenue and cash flow, expands international GMP manufacturing platform

30 July 2026 ·Investor Presentation ·85

Not Assessed Low Score, or missing data

No articles in this tier for the last 12 months.

Market Mentions 2 - appeared in market wrap coverage

These are market wrap articles where Bls Pharmaceuticals (ASX:BLS) was mentioned. They reflect broader market coverage, not company-specific announcements.

Market Wrap - Week 31 (27 July -> 31 July) 2026

1 Aug 2026

Wrap

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

1 Aug 2026

Wrap